A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
作者信息
Stoen Ericson, Kabos Peter, Borden Kelly C, Brown Regina J, Borges Virginia F, Diamond Jennifer R
出版信息
Oncology (Williston Park). 2018 Jun;32(6):298-302.
PMID:29940061
Abstract
摘要
相似文献
1
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Oncology (Williston Park). 2018 Jun;32(6):298-302.
2
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
JACC Heart Fail. 2019 Mar;7(3):217-224. doi: 10.1016/j.jchf.2018.09.001.
3
Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
World J Surg Oncol. 2017 Oct 19;15(1):189. doi: 10.1186/s12957-017-1255-8.
4
ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy.
Ann Surg Oncol. 2019 Dec;26(Suppl 3):804-805. doi: 10.1245/s10434-019-07943-2. Epub 2019 Oct 25.
5
Neoadjuvant and Adjuvant Therapies for Breast Cancer.
South Med J. 2017 Oct;110(10):638-642. doi: 10.14423/SMJ.0000000000000703.
6
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.
7
Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ann Surg Oncol. 2013 Aug;20(8):2562-8. doi: 10.1245/s10434-013-2925-6. Epub 2013 Mar 6.
8
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Breast Cancer Res Treat. 2012 Apr;132(3):863-70. doi: 10.1007/s10549-011-1621-0. Epub 2011 Jun 12.
9
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4.
10
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Breast Cancer Res Treat. 2011 Feb;126(1):109-17. doi: 10.1007/s10549-010-1316-y. Epub 2010 Dec 29.
Zotero 插件